^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HRS-5041

    i
    Other names: HRS-5041, HRS5041, HRS 5041
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    Androgen receptor degrader
    Related drugs:
    Associations

    News

    Trials
    2ms
    Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=63, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HRS-5041 • risvutatug rezetecan (GSK5764227)
    3ms
    A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2026 --> Jun 2027 | Trial primary completion date: Sep 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    docetaxel • abiraterone acetate • prednisone • zeprumetostat (SHR-2554) • HRS-5041 • M9466
    5ms
    A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects (clinicaltrials.gov)
    P1, N=16, Completed, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Completed
    Trial completion
    |
    HRS-5041 • rifampicin
    6ms
    Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=63, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1 trial
    |
    HRS-5041 • risvutatug rezetecan (GSK5764227)
    7ms
    A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=25, Recruiting, Atridia Pty Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HRS-5041
    8ms
    A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Oral HRS-5041 in Healthy Subjects (clinicaltrials.gov)
    P1, N=16, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.
    New P1 trial
    |
    HRS-5041 • rifampicin
    9ms
    A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=25, Not yet recruiting, Atridia Pty Ltd. | Initiation date: Mar 2025 --> Jun 2025
    Trial initiation date
    |
    HRS-5041
    11ms
    HRS-5041-102: Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants (clinicaltrials.gov)
    P1, N=24, Completed, Atridia Pty Ltd. | Active, not recruiting --> Completed
    Trial completion
    |
    HRS-5041
    12ms
    A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=25, Not yet recruiting, Atridia Pty Ltd.
    New P1 trial
    |
    HRS-5041
    1year
    HRS-5041-102: Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, Atridia Pty Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HRS-5041
    1year
    Study of HRS-2189 Combined HRS-5041 in Prostate Cancer (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, Fudan University
    New P2 trial • Metastases
    |
    HRS-2189 • HRS-5041
    over1year
    HRS-5041-102: Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants (clinicaltrials.gov)
    P1, N=24, Recruiting, Atridia Pty Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HRS-5041